Intraoperative Methadone for the Prevention of Postoperative Pain

Sponsor
Brugmann University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05831345
Collaborator
(none)
80
1
2
15.1
5.3

Study Details

Study Description

Brief Summary

The pain felt after orthopedic surgery in the absence of adequate locoregional anesthesia is often insufficiently controlled, especially during the first 24 hours postoperatively.

Methadone, due to its long half-life, may provide better pain control after orthopedic surgery when associated locoregional anesthesia cannot be performed.

It may be impossible to perform loco-regional anesthesia in various contexts: patient refusal, pre-existing neurological impairment, infection at the injection site, coagulopathies, inability to cooperate, total language barrier, allergy to anesthetics, unavailability of equipment (ultrasound, etc.) or equipped room, lack of experience of nursing staff in performing the block and in the postoperative management of the patient.

Intraoperative administration of methadone in these settings may be superior to sufentanil for pain control during the 24 hours post orthopedic surgery, and the pain control provided by methadone does not appear to imply a higher likelihood of adverse events related to opioids.

Condition or Disease Intervention/Treatment Phase
  • Drug: Methadone Hydrochloride
  • Drug: Sufentanil Citrate
Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Supportive Care
Official Title:
Intraoperative Methadone for the Prevention of Postoperative Pain: a Randomized, Double-blind Clinical Study in Orthopedic Surgery
Actual Study Start Date :
Feb 28, 2023
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: S Group

Patients receiving sufentanil during induction of general anesthesia

Drug: Sufentanil Citrate
Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy

Experimental: M Group

Patients receiving methadone during induction of general anesthesia

Drug: Methadone Hydrochloride
Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy

Outcome Measures

Primary Outcome Measures

  1. Total morphine consumption [72 hours]

    Total morphine consumption

  2. Standard visual analogue scale (VAS) [24 hours]

    Pain is assessed using a standard visual analogue scale (VAS) in 11 points (from 0 (no pain) to 10 (worst pain))

Secondary Outcome Measures

  1. Patient satisfaction [72 hours]

    Patient satisfaction is assessed by means of a questionnaire at the end of hospital stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age between 18 and 80 years old

  • ASA 1-3 status

  • Elective partial or total hip and knee arthroplasty

Exclusion Criteria:
  • Patient refusal

  • Preoperative renal failure (serum creatinine > 2 mg/dL or 1.5-fold

  • Increase in basal plasma creatinine or GFR < 90 ml/min/1.73m2)

  • Significant hepatic dysfunction (PT <50% or increase in 3 times basal transaminases)

  • Known heart failure

  • Preoperative hemodynamic instability (preoperative use of inotropes or vasopressors)

  • Known methadone or sufentanil allergy

  • Preoperative opioid use or history of opioid abuse

  • Pregnancy and breastfeeding.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Brugmann Brussels Belgium 1020

Sponsors and Collaborators

  • Brugmann University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tatiana Besse-Hammer, Head Physician of the Clinical Research Unit, Brugmann University Hospital
ClinicalTrials.gov Identifier:
NCT05831345
Other Study ID Numbers:
  • CHUB-Methadone
First Posted:
Apr 26, 2023
Last Update Posted:
Apr 26, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 26, 2023